UNIT 14.11 Genetically Engineered Mouse Models of Ovarian Cancer and Their Utility in Drug Discovery

  1. Sanja Šale

Published Online: 1 JUN 2009

DOI: 10.1002/0471141755.ph1411s45

Current Protocols in Pharmacology

Current Protocols in Pharmacology

How to Cite

Šale, S. 2009. Genetically Engineered Mouse Models of Ovarian Cancer and Their Utility in Drug Discovery. Current Protocols in Pharmacology. 45:14.11:14.11.1–14.11.14.

Author Information

  1. Department of Cell Biology, Harvard Medical School, Boston, Massachusetts

Publication History

  1. Published Online: 1 JUN 2009
  2. Published Print: JUN 2009


Ovarian cancer is the fourth most common cancer in women and the most lethal gynecological malignancy. The high mortality rate is attributable to the asymptomatic nature of the early stage of the disease, the lack of reliable screening tests, and the development of drug resistance. Approximately 90% of ovarian cancers are thought to originate from the ovarian surface epithelia (OSE). Development of in vivo experimental models that accurately recapitulate genetic events that occur during human epithelial ovarian cancer (EOC) initiation and progression is crucial for a better understanding of EOC pathogenesis, identification of early disease markers, and development of more effective therapy. Historically, one of the most challenging problems in developing genetically engineered mouse models (GEMMs) of EOC has been the lack of tissue-specific promoters that regulate transgene expression exclusively in adult OSE cells. Recent improvements in gene delivery technology have greatly accelerated development of GEMMs of EOC. This unit describes two distinct methods of transforming OSE cells in GEMMs and the potential applications of these models in oncology drug discovery and development. Curr. Protoc. Pharmacol. 45:14.11.1-14.11.14. © 2009 by John Wiley & Sons, Inc.


  • epithelial ovarian cancer (EOC);
  • genetically engineered mouse models (GEMMs);
  • ovarian surface epithelium (OSE);
  • specific genetic lesions;
  • RCAS/TVA gene delivery system;
  • Ad-CRE